Regeneron stock sinks after cancer trial miss prompts selloff
Regeneron Pharmaceuticals shares lost 9.8% Monday. The company’s late-stage melanoma drug trial missed its main goal, putting new pressure on a pipeline that investors have seen as a key growth driver.